Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Clinical trial NCT04324151 · RECRUITING

Trial details

NCT number: NCT04324151
Sponsor: Hunan Province Tumor Hospital
Status: RECRUITING
Study type: OBSERVATIONAL

Non Small Cell Lung Cancer

Start date: 2020-03-24
Primary completion: 2024-12-24
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.